Large-cell carcinoma of the lung: A diagnostic category redefined by immunohistochemistry and genomics

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 4, 2014, Pages 324-331

  Sholl, Lynette M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

genomics; immunohistochemistry; large cell carcinoma

Indexed keywords

BASALOID CARCINOMA; CANCER CLASSIFICATION; CANCER GENETICS; CLEAR CELL CARCINOMA; GENE MUTATION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; LYMPHOEPITHELIOMA; REVIEW; ADENOCARCINOMA; CARCINOMA, LARGE CELL; CELL DIFFERENTIATION; DIFFERENTIAL DIAGNOSIS; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; PROTEOMICS;

TUMOR MARKER;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901818790     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000068     Document Type: Review

References (62)

1. Percy C, Sobin L. Surveillance, epidemiology, and end results lung cancer data applied to the World Health Organization's classifications of lung tumors. J Natl Cancer Inst 1983; 70:663-666.
2. Larsson S, Zettergren L. Histological typing of lung cancer. Application of the World Health Organization classification to 479 cases. Acta Pathol Microbiol Scand A 1976; 84:529-537.
3. Campobasso O, Invernizzi B, Musso M, Berrino F. Survival rates of lung cancer according to histological type. Br J Cancer 1974; 29:240-246.
4. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982; 77:123-136.
5. Kung IT, So KF, Lam TH. Lung cancer in Hong Kong Chinese: mortality and histological types. Br J Cancer 1984; 50:381-388.
6. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18:1059-1068.
7. Travis W, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press; 2004.
8. National Cancer Institute. SEER cancer statistics review 1975-2009. Bethesda, MD: National Cancer Institute; 2011.
9. Muscat JE, Stellman SD, Zhang ZF, et al. Cigarette smoking and large cell carcinomaof the lung. Cancer Epidemiol Biomarkers Prev 1997; 6:477-480.
10. Hwang DH, Szeto DP, Perry AS, et al. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid subtype adenocarcinoma. Arch Pathol Lab Med 2013. [Epub ahead of print]
11. Rekhtman N, Tafe LJ, Chaft JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2013; 26:511-522.
12. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009; 22:709-717.
13. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244-285.
14. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall-cell lung cancer. J Clin Oncol 2009; 27:6251-6266.
15. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous nonsmall cell lung cancer. J Thorac Oncol 2011; 6:64-70.
16. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV nonsmall cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5 Suppl.):e341S-e3681S.
17. NCCN guidelines: nonsmall cell lung cancer, version 2. 2013. Available at http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. [Accessed 10 March 2013]
18. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15:529-553.
19. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988; 90:641-652.
20. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in nonsmall cell lung cancer. The LCSG experience. Chest 1994; 106 (6 Suppl.):367S-371S.
21. Wertzel H, Grahmann PR, Bansbach S, et al. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression. Eur J Cardiothorac Surg 1997; 12:698-702.
22. Wick MR, Berg LC, Hertz MI. Large cell carcinoma of the lung with neuroendocrine differentiation. A comparison with large cell 'undifferentiated' pulmonary tumors. Am J Clin Pathol 1992; 97:796-805.
23. Jiang SX, Kameya T, Shoji M, et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998; 22:526-537.
24. Harada M, Yokose T, Yoshida J, et al. Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung. Lung Cancer 2002; 38:177-184.
25. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 2007; 84:702-707.
26. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22:934-944.
27. Chen FF, Yan JJ, Lai WW, et al. Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated 'lymphoepithelioma-like' carcinoma as a distinct entity with better prognosis. Cancer 1998; 82:2334-2342.
28. Chan JK, Hui PK, Yip TT, et al. Detection of Epstein-Barr virus only in lymphoepithelial carcinomas among primary carcinomas of the lung. Histo-pathology 1995; 26:576-578.
29. Chan JK, Hui PK, Tsang WY, et al. Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases. Cancer 1995; 76:413-422.
30. Gomez-Roman JJ, Martinez MN, Fernandez SL, Val-Bernal JF. Epstein-Barr virus-associated adenocarcinomas and squamous-cell lung carcinomas. Mod Pathol 2009; 22:530-537.
31. Travis WD, Colby TV, Corrin B, et al., editors. World Health Organization International Histological Classification of tumours. Histological typing of lung and pleural tumours. 3rd ed. Lyon: Springer-Verlag; 1999.
32. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol 1992; 23:993-1003.
33. Moro D, Brichon PY, Brambilla E, et al. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 1994; 73:2734-2739.
34. Kim DJ, Kim KD, Shin DH, et al. Basaloid carcinoma of the lung: a really dismal histologic variant? Ann Thorac Surg 2003; 76:1833-1837.
35. Moro-Sibilot D, Lantuejoul S, Diab S, et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 2008; 31:854-859.
36. Yousem SA. Immunohistochemical and molecular characterization of clear cell carcinoma of the lung. Hum Pathol 2013; 44:2467-2474.
37. Deshpande CG, Yoshizawa A, Motoi N, et al. Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant. Mod Pathol 2009; 22 (Suppl. 1):1595.
38. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009; 33:1752-1764.
39. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 1978; 41:1937-1948.
40. Cavazza A, Colby TV, Tsokos M, et al. Lung tumors with a rhabdoid pheno-type. Am J Clin Pathol 1996; 105:182-188.
41. Miyagi J, Tsuhako K, Kinjo T, et al. Rhabdoid tumour of the lung is a dedifferentiated phenotype of pulmonary adenocarcinoma. Histopathology 2000; 37:37-44.
42. Shimazaki H, Aida S, Sato M, et al. Lung carcinoma with rhabdoid cells: a clinicopathological study and survival analysis of 14 cases. Histopathology 2001; 38:425-434.
43. Izquierdo-Garcia FM, Moreno-Mata N, Herranz-Aladro ML, et al. Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of nonsmall cell lung carcinomas and alveolar entrapment. Histol Histopathol 2010; 25:1287-1295.
44. Kodama T, Shimosato Y, Koide T, et al. Large cell carcinoma of the lung-ultrastructural and immunohistochemical studies. Jpn J Clin Oncol 1985; 15:431-441.
45. Delmonte VC, Alberti O, Saldiva PH. Large cell carcinoma of the lung. Ultrastructural and immunohistochemical features. Chest 1986; 90:524-527.
46. Yesner R. Large cell carcinoma of the lung. Semin Diagn Pathol 1985; 2:255-269.
47. Albain KS, True LD, Golomb HM, et al. Large cell carcinoma of the lung. Ultrastructural differentiation and clinicopathologic correlations. Cancer 1985; 56:1618-1623.
48. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
49. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007; 448:561-566.
50. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013; 15:415-453.
51. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 2011; 136:773-782.
52. Rossi G, Mengoli MC, Cavazza A, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and mole cular biology. Virchows Arch 2014; 464:61-68.
53. Johansson M, Dietrich C, Mandahl N, et al. Karyotypic characterization of bronchial large cell carcinomas. Int J Cancer 1994; 57:463-467.
54. Weston A, Willey JC, Modali R, et al. Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 1989; 86:5099-5103.
55. Hou J, Lambers M, den Hamer B, et al. Expression profiling-based subtyping identifies novel nonsmall cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol 2012; 7:105-114.
56. Botling J, Edlund K, Lohr M, et al. Biomarker discovery in nonsmall cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 2013; 19:194-204.
57. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3, 026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012; 18:6169-6177.
58. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1, 683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19:4273-4281.
59. Nishino M, Klepeis VE, Yeap BY, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012; 25:1462-1472.
60. Clinical Lung Cancer Genome Project (CLCGP), NetworkGenomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5:209ra153.
61. Randomized phase II study of AZD6244 MEK-inhibitor with erlotinib in KRAS wild type and KRAS mutant advanced non-small cell lung cancer. 2014. Available at http://clinicaltrials.gov/ct2/show/NCT01229150. [Accessed 20 February 2014]
62. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced nonsmall-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14:38-47.